Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Inclusion Criteria: HCC with diagnosis confirmed pathologically or clinically Patients who need to receive TACE and/or HAIC, or have plans to undergo another treatment (3-6 weeks after the previous treatment) Child Pugh class A or B ECOG PS 0-2 PLT ≤ 75×10^9/L (10 days before interventional therapy) Exclusion Criteria: Thrombocytopenia caused by hematological diseases, non chemotherapy related thrombocytopenia (excluding liver cirrhosis with hypersplenism) PLT <30×10^9/L History of hepatic encephalopathy, refractory ascites, or hepatorenal syndrome History of arterial or venous thrombosis within 6 months Uncontrolled severe infections Pregnant or breastfeeding female patients Immune deficiencies, such as autoimmune diseases, HIV infected individuals, etc Anticoagulation or antiplatelet therapy witch cannot be suspended during the treatment period: heparin, warfarin, rivaroxaban, dipyridamole, non-steroidal anti-inflammatory drugs, aspirin, verapamil, Ticlopidine, clopidogrel, glycoprotein IIb/IIIa antagonists, erythropoietin, etc; Administration of blood products within 7 days prior to the baseline visit (excluding albumin infusion) Allergy to avatrombopag or any of its formulations History (such as gastrointestinal bleeding within 3 months, high risk of thrombosis, such as portal vein main flow velocity<10cm/s) which may affect the safety of the patients or their ability to complete the study